• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NELFINAVIR Drug Record

  • Summary
  • Interactions
  • Claims
  • NELFINAVIR chembl:CHEMBL584 ApprovedAntineoplastic

    Alternate Names:

    VIRACEPT
    NELFINAVIR
    drugbank:00220
    pubchem.compound:64143
    chembl:CHEMBL584
    rxcui:134527
    chemidplus:159989-64-7

    Drug Info:

    (1 More Sources)

    Publications:

    Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.
    Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother
    Mukonzo JK et al., 2013, Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study., BMC Infect Dis
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Ribaudo HJ et al., 2010, Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study., J Infect Dis
    Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis
    Haas DW et al., 2005, Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study., J Infect Dis
    Fellay J et al., 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study., Lancet
    Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.
    Kattel K et al., 2015, Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer., Br J Clin Pharmacol
  • NELFINAVIR   TFAP2A

    Interaction Score: 5.89

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10996400


    Sources:
    NCI

  • NELFINAVIR   TLR4

    Interaction Score: 1.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15388451


    Sources:
    NCI

  • NELFINAVIR   IL6

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15388451


    Sources:
    NCI

  • NELFINAVIR   ABCB1

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17664327 23734829 20860463 20662624 16912956 16267764 11809184


    Sources:
    DTC PharmGKB

  • NELFINAVIR   AKT1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • NELFINAVIR   CYP2C19

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25752914 16267764


    Sources:
    PharmGKB

  • NELFINAVIR   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NCI: NELFINAVIR

    • Version: 14-September-2017

    Alternate Names:
    C29285 NCI drug code

    Drug Info:

    Publications:
    Lenhard et al., 2000, HIV protease inhibitors block adipogenesis and increase lipolysis in vitro., Antiviral Res.
    Equils et al., 2004, Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation., Antimicrob. Agents Chemother.

  • DTC: NELFINAVIR

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL584 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tong L et al., 2007, Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro., Antimicrob Agents Chemother

  • PharmGKB: nelfinavir

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Ribaudo HJ et al., 2010, Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study., J Infect Dis
    Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
    Fellay J et al., 2002, Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study., Lancet

  • TALC: NELFINAVIR

    • Version: 12-May-2016

    Alternate Names:
    NELFINAVIR Primary Drug Name
    NELFINAVIR Drug Generic Name
    VIRACEPT Drug Trade Name

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL584

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21